CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
Want to see CTMX full AI Analyst Report?
Total Valuation
CytomX Therapeutics has a market cap or net worth of $785.91M. The enterprise value is $554.60M.
Market Cap$785.91M
Enterprise Value$554.60M
Share Statistics
CytomX Therapeutics has 217,702,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding217,702,910
Owned by Insiders0.91%
Owned by Institutions33.22%
Financial Efficiency
CytomX Therapeutics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -20.48%.
Return on Equity (ROE)-0.18
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-20.48%
Return on Capital Employed (ROCE)-0.21
Revenue Per Employee640.34K
Profits Per Employee-145.95K
Employee Count119
Asset Turnover0.50
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CytomX Therapeutics is ―. CytomX Therapeutics’s PEG ratio is 0.24.
PE Ratio―
PS Ratio7.71
PB Ratio5.93
Price to Fair Value5.93
Price to FCF-7.75
Price to Operating Cash Flow-7.99
PEG Ratio0.24
Income Statement
In the last 12 months, CytomX Therapeutics had revenue of 76.20M and earned -17.37M in profits. Earnings per share was -0.15.
Revenue76.20M
Gross Profit76.20M
Operating Income-22.36M
Pretax Income-17.13M
Net Income-17.37M
EBITDA-20.99M
Earnings Per Share (EPS)-0.15
Cash Flow
In the last 12 months, operating cash flow was -80.09M and capital expenditures -101.00K, giving a free cash flow of -80.19M billion.
Operating Cash Flow-80.09M
Free Cash Flow-80.19M
Free Cash Flow per Share-0.37
Dividends & Yields
CytomX Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.57
52-Week Price Change69.48%
50-Day Moving Average4.95
200-Day Moving Average3.74
Relative Strength Index (RSI)53.45
Average Volume (3m)10.71M
Important Dates
CytomX Therapeutics upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
CytomX Therapeutics as a current ratio of 3.09, with Debt / Equity ratio of 0.89%
Current Ratio3.09
Quick Ratio3.09
Debt to Market Cap<0.01
Net Debt to EBITDA0.40
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CytomX Therapeutics has paid 238.00K in taxes.
Income Tax238.00K
Effective Tax Rate-0.01
Enterprise Valuation
CytomX Therapeutics EV to EBITDA ratio is -27.60, with an EV/FCF ratio of -7.64.
EV to Sales7.60
EV to EBITDA-27.60
EV to Free Cash Flow-7.64
EV to Operating Cash Flow-7.66
Balance Sheet
CytomX Therapeutics has $346.71M in cash and marketable securities with $2.86M in debt, giving a net cash position of $343.85M billion.
Cash & Marketable Securities$346.71M
Total Debt$2.86M
Net Cash$343.85M
Net Cash Per Share$1.58
Tangible Book Value Per Share$0.71
Margins
Gross margin is 99.29%, with operating margin of -29.35%, and net profit margin of -22.79%.
Gross Margin99.29%
Operating Margin-29.35%
Pretax Margin-22.48%
Net Profit Margin-22.79%
EBITDA Margin-27.54%
EBIT Margin-29.35%
Analyst Forecast
The average price target for CytomX Therapeutics is $13.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.00
Price Target Upside169.71% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast-75.91%
EPS Growth Forecast-173.33%